NCT01995266 - Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual | Biotech Hunter

Enrollment

218

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Hepatitis C

Interventions

DRUG

Asunaprevir

DRUG

Daclatasvir

Trial Locations (38)

736

Local Institution, Tainan City

807

Local Institution, Kaohsiung City

100015

Local Institution, Beijing

100034

Local Institution, Beijing

100039

Local Institution, Beijing

100050

Local Institution, Beijing

100054

Local Institution, Beijing

110000

Local Institution, Shenyang

130021

Local Institution, Changchun

200025

Local Institution, Shanghai

200235

Local Institution, Shanghai

210002

Local Institution, Nanjing

210003

Local Institution, Nanjing

210029

Local Institution, Nanjing

300192

Local Institution, Tianjin

400038

Local Institution, Chongqing

410008

Local Institution, Changsha

410011

Local Institution, Changsha

430022

Local Institution, Wuhan

510060

Local Institution, Guangzhou

510515

Local Institution, Guangzhou

510630

Local Institution, Guangzhou

710038

Local Institution, Xi'an

Local Institution, Beijing

710061

Local Institution, Xi'an

Local Institution, Shanghai

140-743

Local Institution, Seoul

602-715

Local Institution, Busan

137-701

Local Institution, Seoul

700-712

Local Institution, Daegu